Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Institute of Liver Studies, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Transplantation. 2019 Apr;103(4):e89-e98. doi: 10.1097/TP.0000000000002559.
Patients who receive a liver transplant for hepatocellular carcinoma (HCC) often receive poorer-quality livers. Tumor recurrence also has a negative effect on posttransplant outcomes. We compared mortality of HCC and non-HCC recipients in different posttransplant time periods (epochs) to separate the impact of these different risk factors on short-term and longer-term posttransplant survival.
We identified a population-based cohort of first-time liver transplant recipients (aged ≥16 years) between 2008 and 2016 in the United Kingdom. We used Cox regression to estimate hazard ratios (HRs) comparing posttransplant mortality between HCC and non-HCC patients in 3 posttransplant epochs: 0 to 90 days, 90 days to 2 years, and 2 to 5 years, with adjustment first for recipient and later also for donor characteristics.
One thousand two hundred seventy HCC and 3657 non-HCC transplant recipients were included. Five-year posttransplant survival was 74.5% (95% confidence interval [CI] 71.2%-77.5%) in HCC patients and 84.6% (83.0%-86.1%) in non-HCC patients. With adjustment for recipient characteristics only, mortality of HCC patients was lower but not statistically significantly different in the first 90 days (HR, 0.76; 95% CI, 0.53-1.09; P = 0.11), but significantly higher thereafter (90 days to 2 years: HR, 1.99; 95% CI, 1.48-2.66; P < 0.001; 2 to 5 years HR, 1.77; 95% CI, 1.30-2.42; P < 0.001). Further adjustment for donor characteristics had little impact on these results.
HCC recipients have poorer 5-year posttransplant survival than non-HCC recipients, most likely because of tumor recurrence. The more frequent use of poorer-quality donor organs for HCC does not explain this difference.
接受肝移植治疗肝细胞癌 (HCC) 的患者通常会接受质量较差的肝脏。肿瘤复发对移植后的结果也有负面影响。我们比较了不同移植后时期 (时期) HCC 和非 HCC 受者的死亡率,以将这些不同的风险因素对短期和长期移植后生存的影响分开。
我们确定了 2008 年至 2016 年期间在英国进行的首次肝移植受者 (年龄≥16 岁) 的基于人群的队列。我们使用 Cox 回归估计了在移植后 3 个时期 HCC 和非 HCC 患者之间的移植后死亡率的风险比 (HR):0 至 90 天、90 天至 2 年和 2 至 5 年,首先调整受者特征,然后调整供者特征。
纳入了 1277 例 HCC 和 3657 例非 HCC 移植受者。HCC 患者的 5 年移植后生存率为 74.5% (95%CI 71.2%-77.5%),而非 HCC 患者为 84.6% (83.0%-86.1%)。仅调整受者特征后,HCC 患者在前 90 天的死亡率较低,但无统计学意义 (HR,0.76;95%CI,0.53-1.09;P = 0.11),但此后死亡率显著升高 (90 天至 2 年:HR,1.99;95%CI,1.48-2.66;P<0.001;2 至 5 年 HR,1.77;95%CI,1.30-2.42;P<0.001)。进一步调整供者特征对这些结果影响不大。
与非 HCC 受者相比,HCC 受者的 5 年移植后生存率较差,这很可能是由于肿瘤复发。更频繁地使用质量较差的供体器官治疗 HCC 并不能解释这种差异。